文献速递骨质疏松与代谢性骨病

罗莫佐单抗与特立帕肽治疗骨质疏松的全因死亡率比较:真实世界倾向评分匹配队列研究

Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study.
PubMed 文献 · Osteoporos Int · 2026-04-10

本研究利用TriNetX美国协作网络电子病历数据,纳入2016至2023年启动罗莫佐单抗或特立帕肽的骨质疏松患者,经1:1倾向评分匹配后每组2470例。结果显示罗莫佐单抗组全因死亡率显著低于特立帕肽组(HR 0.68,95%CI 0.49-0.94),在≥60岁患者中更明显(HR 0.65,95%CI 0.47-0.88),且未增加心血管风险。

要点

  • 罗莫佐单抗较特立帕肽显著降低骨质疏松患者全因死亡率(HR 0.68)。
  • ≥60岁患者生存优势更明显(HR 0.65),合并糖尿病或慢性肾病者趋势一致但未达统计学显著。
  • 高血压或冠心病患者未观察到死亡率升高,提示心血管安全性良好。

核心结论

  • 在真实世界骨质疏松患者中,罗莫佐单抗相比特立帕肽与显著更低的全因死亡风险相关。

研究设计与样本

  • 回顾性队列研究,使用TriNetX美国协作网络超过120家医疗机构的电子病历数据。
  • 纳入2016年1月1日至2023年12月31日诊断为骨质疏松并启动罗莫佐单抗或特立帕肽、年龄≥20岁的患者。
  • 排除恶性肿瘤、骨肿瘤、多发性骨髓瘤、甲状旁腺疾病或脑血管意外者,经1:1倾向评分匹配后每组2470例。

主要发现

  • 罗莫佐单抗组全因死亡率显著低于特立帕肽组(HR 0.68,95%CI 0.49-0.94)。
  • 年龄≥60岁患者中罗莫佐单抗的生存优势更明显(HR 0.65,95%CI 0.47-0.88)。
  • 糖尿病、慢性肾病等亚组分析一致倾向罗莫佐单抗但未达统计学显著。
  • 高血压或冠心病患者中未观察到罗莫佐单抗增加死亡风险。

临床怎么用

  • 在骨质疏松药物治疗选择中,可考虑优先选用罗莫佐单抗以降低死亡风险,尤其对≥60岁或骨折高风险患者。
  • 使用罗莫佐单抗前仍应仔细评估心血管风险。

局限性

  • 研究为回顾性设计,存在固有局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study compared romosozumab and teriparatide for osteoporosis treatment using real-world data. Romosozumab was linked to significantly lower mortality, especially in older adults, without added cardiovascular risk. These findings highlight romosozumab as a potentially safer and more effective option for reducing death risk in patients with osteoporosis. BACKGROUND: Osteoporosis is a prevalent condition among older adults and significantly increases the risk of fragility fractures, particularly affecting the hip and vertebrae. Pharmacologic therapy remains central to osteoporosis management, with anabolic agents such as romosozumab and teriparatide demonstrating efficacy in increasing bone mineral density and reducing fracture risk. However, direct comparative evidence regarding their impact on mortality is limited. This study aimed to evaluate the differences in all-cause mortality between romosozumab and teriparatide in patients with osteoporosis, utilizing a large real-world dataset. METHODS: We conducted a retrospective cohort study using electronic medical records from the TriNetX US Collaborative Network, comprising data from over 120 healthcare organizations. Patients aged ≥ 20 years diagnosed with osteoporosis between January 1, 2016, and December 31, 2023, initiating either romosozumab or teriparatide were included. Individuals with malignancies, bone neoplasms, multiple myeloma, parathyroid disorders, or cerebrovascular accidents were excluded. Propensity score matching (1:1) balanced demographic, clinical, and laboratory characteristics between cohorts. The primary outcome was all-cause mortality, with subgroup analyses performed based on age, sex, comorbidities, and treatment settings. RESULTS: Each treatment group included 2470 matched patients. Over the follow-up period, romosozumab was associated with significantly lower all-cause mortality compared to teriparatide (hazard ratio [HR] 0.68, 95% CI 0.49-0.94). This survival advantage was particularly evident in patients aged ≥ 60 years (HR 0.65, 95% CI 0.47-0.88). Subgroup analyses consistently favored romosozumab across multiple comorbid conditions, including diabetes mellitus and chronic kidney disease, although these subgroup results did not reach statistical significance. Importantly, no increased mortality risk was observed in patients with hypertension or coronary heart disease, indicating a favorable cardiovascular safety profile in these populations. CONCLUSION: In this real-world analysis, romosozumab was associated with a significantly lower risk of all-cause mortality compared to teriparatide among patients with osteoporosis. These findings may support the preferential consideration of romosozumab, particularly for older adults and patients at elevated fracture risk, given the inherent limitations of the study design, while highlighting the necessity of careful cardiovascular risk assessment.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Tsai SHL, Chen YH, Yang CY, et al. Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study. Osteoporos Int. 2026. PMID: 41961089. doi:10.1007/s00198-026-07968-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。